chartexchange

AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT

Pharmaceutical Technology | Nov 13, 2026 2:53 PM EST

KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.

Read original article